McCann Health tapped its first global chief digital officer, highlighting an increase in digital business from pharma clients.
Merck & Co.'s Keytruda posted some new melanoma data that could help it play catch-up with Bristol-Myers' Opdivo.
AstraZeneca and Merck's first-in-class ovarian cancer drug Lynparza just won a coveted approval to treat BRCA-mutated breast cancer.
Think you saw a lot of TV ads for drugs in 2017? That's because you did.
BMS’s Opdivo is the only immuno-oncology drug approved to treat kidney cancer, but more rivals are threatening that status.
There's "still significant growth ahead” for next-gen anticoagulant Eliquis, the way Bristol-Myers Squibb CEO Giovanni Caforio sees it.
Allscripts is shelling out $100 million for head-to-head EHR Practice Fusion, adding 30,000 physician practices to its portfolio.
Alexion’s rollout of Soliris in generalized myasthenia gravis won’t be just any launch for the rare-disease product, or so the company hopes.
Jennifer Aniston's front and center in Shire's latest "eyelove" creative, promoting dry eye awareness with some chat about her personal…
The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.